RE: bad day, good dayI gotta step in, LargeInvest. Your last post is nonsense. It is truly nonsense. This has nothing to do with who rules the forum or any of that sort of stuff. It has everything to do with trying to make rational deductions based real information. For the record, here's what you posted:
I would agree with you, Don wants it done by end of June, lets see if he keeps his deadlines for once. LOL. A few days ago I told Theresa the lowest I expected to get for the company was $35, she then hinted it was slightly higher then that. So your $40 is bang on, it seems that bid wasn't rejected after all.
First of all, Don wanted the deal done two or three years ago, so yeah, he wants it done by the end of June, or the end of July if it can't be done by the end of June, or the end of August if... etc etc etc. Like all of us, he would like the deal done sooner than later. So would the pharmas. They don't want to pay $300 per share after Phase II or even $100 after Phase I. But this financing signals a patience on the parts of DM and rest of RVX that has sent a signal to the pharmas. Until RVX gets a high firm bid, the last thing they would ever telegraph to a potential bidder is a deadline. That immediately cuts the bidding price. The financing makes it clear that there is no deadline. Of course, after a great bid is received, then the others have only so long to consider what their bids might be, but that's a different situation. Remember that the research and trials go on no matter who owns RVX. Time affects nothing but the price, waiting is good.
And you say $40 is "bang on"!! Bang on what? Bang on the borders of stupidity, that's what? What would you expect an officer of the company to say, that it was a lot higher than that? Twice that? Think about it. In terms of 2003 US dollars, at $40 we would be getting the equivalent of $900 million, $400 million less than Esperion fetched. If Esperion's drugs work, so will RVX's drugs. If Esperion's drugs fail, RVX's drugs still have a high likelihood of succeeding by virtue of the method of discovery, the resulting huge suite of candidates from which to choose lead candidates and by virtue of the method by which Apo-A1 is expressed through NexVas. And this doesn't consider the large molecule issue for Esperion which really leaves the HDL market wide open for RVX's small molecule drugs.
Simply put, RVX is worth more than Esperion. Pfizer expressed an opinion about the value of Esperion. They put their number on a cheque, $1.3 billion USD, about $1.7 billion in CDN dollars back in 2003, or just under $60 per share. I trust Pfizer's opinion about the market value of regulating Apo-A1 far more than I trust your judgement, LargeInvest. Pfizer cannot walk away from that opinion.
Since Esperion was bought, RVX has immensely increased the quantity and value of its intellectual property. To think that we won't get something north of what Esperion got, something north of $60, is quite preposterous.
And then you finish with this gem, "it seems that bid wasn't rejected after all." referring to $40. If there has been a formal offer it must be announced. There has been no formal bid to accept or reject. But we all know how that really works. A potential buyer asks UBS or perhaps asks DM, "Don, would you consider a bid of $60?" That is not a bid. That's hypothetical. Don would say, "Gosh, Mr. Merck, I know that it would be pointless for me to take that to the board. You're all nice folks over there at Merck, but, it ain't enough." That's just talk, Large. For you to have any knowledge of a bid being offered, hypothetically or otherwise, for you to know its amount or for you to know whether it was turned down or otherwise knowing whether it's even a starting point for either bidding or negotiations, it's impossible for you to know any of this.
Theresa Kennedy gave you precisely nothing and you've taken her words and made certain deductions which have precisely that same value.